← FDA DRUG APPROVALS

FDA ANDA · ANDA212957

FOSAPREPITANT DIMEGLUMINE

Sponsor: NAVINTA LLC

APPLICATION
ANDA212957
TYPE
ANDA
ORIGINAL APPROVAL
2020-08-20
LATEST ACTION
2020-08-20
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Discontinued

Products

FOSAPREPITANT DIMEGLUMINEDiscontinued
FOSAPREPITANT DIMEGLUMINE EQ 150MG BASE/VIAL · POWDER · INTRAVENOUS

Approval history

2020-08-20UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →